A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

It’s not yet known how many people have gotten sick in the Texas measles outbreak, but there are at least 215 confirmed cases since late January.

Follow the latest news headlines from Australia's most trusted source. Read in-depth expert analysis and watch live coverage on ABC News.

Lenacapavir' was developed by Gilead Sciences, a research-based biopharmaceutical company in the US, as a pre-exposure prophylaxis (PrEP) medication to prevent infection in people at risk of exposure ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

An annual injection to prevent HIV infection is closer to becoming reality after the first stage of a drug trial showed promising results.

COVID-19 took the lives of more than one million Americans and nearly 116,000 Californians, according to the Centers for Disease Control and Prevention.

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...